Endometriosis.
Level 5 - mechanism / opinion, no new human data
Narrative review of disease mechanisms and management without systematic search or primary empirical data.
PubMed 30994890 · doi:10.1210/er.2018-00242
What was done
This narrative review synthesizes the cellular, epigenetic, genetic, and endocrine mechanisms underlying pelvic endometriosis, alongside current clinical management strategies for associated pain and infertility.
What was found
The abstract reports no quantitative empirical numbers or effect sizes. It details qualitative molecular mechanisms: stromal cells exhibit epigenetic alterations (GATA-binding factor-6 overexpression, steroidogenic factor-1 overexpression driving inflammation via estrogen receptor-beta, and progesterone receptor deficiency causing progesterone resistance), while epithelial cells harbor somatic cancer-driver mutations (such as KRAS). Clinical management relies on surgical lesion removal, suppression of ovulation and estrogen, cyclooxygenase inhibitors, and in vitro fertilization.
Why it matters
The paper outlines how epigenetic dysregulation in stroma and somatic mutations in epithelium drive endometriosis pathophysiology, highlighting targets for future molecular therapies and preventive suppression.
Limits
This is a narrative review without systematic search criteria, quantitative meta-analysis, or primary data. The interaction between defective stromal cells and mutated epithelial cells remains uncharacterized, and treatment comparative efficacy is not quantitatively evaluated.
Cited by
- supports Endometriosis is the leading cause of chronic pelvic pain and the leading cause of infertility in women.